TICKERNERD
Menu
KIDSKIDSHealthcare · Medical Devices

KIDS Stock Forecast: OrthoPediatrics Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$26
−2.21% on the day

The 9 Wall Street analysts covering OrthoPediatrics Corp. hold a median 12-month price target of $25 — -2.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$669.7M
Ticker Nerd rank
62 / 100
Median analyst target
$25
Analysts covering
9
Total return, dividends reinvested
1W
+3.4%
1M
+31.6%
YTD
+44.4%
1Y
+33.9%
From 52W high
−3.2%
From 52W low
+75.2%
$15
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KIDS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OrthoPediatrics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Accruals
69
Volatility
60
Momentum
59
Value
57
Quality
53
Revisions
51
Size
51
Issuance
30

Growth (82): Sales and profits are climbing, and climbing faster than before.

Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KIDS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KIDS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26KIDSHigh $35Median $25Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $22Median $25High $35

The green dot is the last close — the median target sits −2.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Aug 2026BTIGMaintainsBuy$24 → $29
5 Aug 2026NeedhamMaintainsBuy—
5 Aug 2026NeedhamMaintainsBuy$30 → $35
5 Aug 2026Piper SandlerReiteratesOverweight—
5 Aug 2026Piper SandlerReiteratesOverweight$22 → $25
16 July 2026Truist SecuritiesMaintainsHold—
16 July 2026Truist SecuritiesMaintainsHold$17 → $20
1 May 2026BTIGReiteratesBuy—
1 May 2026BTIGReiteratesBuy$24
2 Mar 2026Truist SecuritiesMaintainsHold—
27 Feb 2026BTIGMaintainsBuy—
27 Feb 2026NeedhamMaintainsBuy—
27 Jan 2026TD CowenInitiatesBuy—
10 Dec 2025Canaccord GenuityInitiatesBuy—
29 Oct 2025BTIGReiteratesBuy—
29 Oct 2025NeedhamMaintainsBuy—
10 Oct 2025BTIGMaintainsBuy—
10 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
10 Oct 2025Lake StreetMaintainsBuy—
10 Oct 2025Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KIDS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KIDS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

OrthoPediatrics Corp. (KIDS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
246.3×

Cheaper than 3% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
−1651.7×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
15.4%

Higher than 63% of US stocks

Earnings growth (YoY)
15.4%

Higher than 54% of US stocks

Gross margin
74.3%

Higher than 87% of US stocks

Operating margin
−5.8%

Higher than 27% of US stocks

Net margin
−15.7%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−11.4%

Higher than 35% of US stocks

Return on assets
−2.8%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KIDS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
KIDSOrthoPediatrics Corp.$669.7M
62
CTKBCytek Biosciences, Inc.$621.2M
65
SSIISS Innovations International, Inc.$694.1M
17
DCTHDelcath Systems, Inc.$591.7M
96
AHCOAdaptHealth Corp.$765.2M
51
CERSCerus Corp.$539.8M
90
TCMDTactile Systems Technology, Inc.$537.3M
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OrthoPediatrics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KIDS news & analysis

OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter

MarketBeat · 14 Aug 2026positive

OrthoPediatrics reported record revenue, adjusted EBITDA and number of children helped in Q2, with CEO Dave Bailey noting at the Canaccord Genuity Growth Conference that the company is seeing early contributions from its newer "super cycle" products, marking an inflection point.

Why it matters — The record results and early contributions from new "super cycle" products signal that OrthoPediatrics may be entering a period of accelerated growth, which is important for investors watching the company's trajectory.

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published a transcript of OrthoPediatrics Corp.'s (KIDS) Q2 2026 earnings call, covering the company's quarterly update. The transcript documents the company's earnings call proceedings for that quarter.

Why it matters — A KIDS watcher can review the full earnings call transcript for management commentary on the company's second-quarter results.

OrthoPediatrics Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

OrthoPediatrics reported record second-quarter revenue of $70.5 million, a 15% year-over-year increase, driven by strong Trauma & Deformity and specialty bracing results despite a decline in scoliosis revenue. The company also raised its 2026 revenue outlook while maintaining its adjusted EBITDA and free-cash-flow targets.

Why it matters — The record revenue and raised outlook signal stronger-than-expected operational performance and management's confidence in the company's growth trajectory.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 5 Aug 2026neutral

OrthoPediatrics reported a Q2 loss of $0.26 per share, which was narrower than the Zacks Consensus Estimate of a $0.31 loss but wider than the $0.11 loss per share it posted a year earlier. The headline notes the company topped revenue estimates for the quarter.

Why it matters — KIDS watchers would care because the company's quarterly results beat analyst expectations despite a year-over-year widening of its loss.

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

GlobeNewsWire · 4 Aug 2026positive

OrthoPediatrics Corp. announced its second quarter 2026 financial results for the period ended June 30, 2026, and increased its 2026 financial guidance. The announcement was made via press release on Aug. 04, 2026.

Why it matters — The company raised its full-year 2026 financial guidance, an update that KIDS watchers would want to know when tracking the company's outlook.

FAQ

Frequently asked questions about KIDS stock

What is the KIDS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering OrthoPediatrics Corp. have a median 12-month price target of $25, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KIDS stock a buy right now?

Of the 9 analysts covering OrthoPediatrics Corp., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OrthoPediatrics Corp. 62 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KIDS?

As at 22 Aug 2026, OrthoPediatrics Corp. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will KIDS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -2.5% from the last close, and Ticker Nerd's factor model ranks OrthoPediatrics Corp. 62 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KIDS stock forecast for 2030?

No analyst covering OrthoPediatrics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KIDS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.

How has KIDS stock performed over the past year?

OrthoPediatrics Corp. returned +33.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OrthoPediatrics Corp. do?

OrthoPediatrics Corp. is a specialized orthopedic medical device company focusing on the pediatric market.

What is the latest news on KIDS?

The most recent item we track (MarketBeat, 14 Aug 2026): "OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter". OrthoPediatrics reported record revenue, adjusted EBITDA and number of children helped in Q2, with CEO Dave Bailey noting at the Canaccord Genuity Growth Conference that the company is seeing early contributions from its newer "super cycle" products, marking an inflection point.

Company

About OrthoPediatrics Corp.

OrthoPediatrics Corp. is a specialized orthopedic medical device company focusing on the pediatric market. The company is dedicated to advancing the field of pediatric orthopedics by developing and marketing products specifically designed to treat musculoskeletal conditions in children. OrthoPediatrics Corp.'s product portfolio includes a wide range of innovative solutions for trauma and deformity correction, complex spine conditions, and sports medicine. These products are crucial for ensuring that children receive appropriate and tailored care, which can significantly impact their long-term physical development. Primarily serving hospitals and orthopedic surgeons, OrthoPediatrics plays a critical role in advancing medical care for younger demographics. Marketed globally, the company's products support a sometimes underrepresented segment within the medical device industry, emphasizing safety, efficacy, and child-specific design. By focusing exclusively on pediatric orthopedics, OrthoPediatrics Corp. holds a unique position in the health care market, addressing a specialized need and striving to improve the quality of life and outcomes for young patients worldwide.

CEO Mr. David R. Bailey · 602 employees · United States · https://www.orthopediatrics.com